A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
Latest Information Update: 22 Aug 2024
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Glecirasib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
- 20 Aug 2024 Planned End Date changed from 1 Jan 2026 to 1 Dec 2024.
- 20 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2023 Results presented in a Jacobio Pharmaceuticals media release,